NRAS Q61R clinical trials at UCSF

1 research study open to eligible people

NRAS Q61R is a change in the NRAS gene at position 61 that can drive cancer. UCSF is running a first-in-human Phase 1 study of a new drug for tumors with this mutation. The study checks safety, side effects, and how the body handles the drug.

Showing trials for

  • First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

    open to eligible people ages 18 years and up

    This is a Phase 1 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of RLY-8161, an NRAS-selective inhibitor, in participants with advanced NRAS-mutant melanoma and other solid tumors.

    San Francisco, California and other locations

Last updated: